ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...

Pfizer's deliberations, which previously have not been disclosed, offer a rare window into the frustrating search for Alzheimer's treatments inside one of the world's largest drug companies. Despite ...

Colorado finalized the nation’s first prescription drug price cap Oct. 3, establishing an upper payment limit for Enbrel, an autoimmune medication, through the state’s prescription drug affordability ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

As a physician, I have seen firsthand the challenges and inequities of our health-care system. But nothing prepared me for the experience of navigating it myself while seeking treatment for a ...

DENVER — Colorado became the first state in the country Friday to set a maximum price that insurers and patients can pay for a prescription medication — a move that’s likely to face lawsuits. The ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.